FIELD: medicine; oncology.
SUBSTANCE: group of inventions can be used to detect the presence or absence of a solid malignant tumor in a subject, such as prostate cancer (PCa). That is ensured by sampling a biological sample at the first and second time points. Then presence of at least one biomarker of solid malignant tumor is determined. Biomarker is selected from macrophage inhibitory cytokine 1 (mic-1), total PSA and beta-microsemiprotein (msmb). Combined indicator reflecting change of biomarker concentration between time points is generated. Time interval between the time points ranges from 10 days to 3 months. Combined indicator is compared to the value in the control sample. Also disclosed is a method for detecting the presence or absence of PCa in a subject.
EFFECT: group of inventions enables the initial diagnosis of prostate cancer in a subject.
21 cl, 1 tbl, 4 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA | 2016 |
|
RU2647433C1 |
| METHOD OF DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA | 2016 |
|
RU2646790C1 |
| METHOD FOR PREDICTION OF RISK OF BIOCHEMICAL RECURRENT IN PROSTATE CANCER PATIENTS AFTER RADIATION AND HORMONE THERAPY | 2015 |
|
RU2605838C1 |
| REAGENT KIT FOR DETECTING A MARKER OF EPITHELIAL CARCINOMAS | 2018 |
|
RU2735918C2 |
| METHOD FOR DETERMINING PRESENCE OR ABSENCE OF AGGRESSIVE PROSTATE CANCER | 2013 |
|
RU2675370C2 |
| METHOD FOR PREOPERATIVE DETERMINATION OF MORPHOLOGICAL RISK FACTORS FOR PROGRESSION IN PATIENTS WITH PROSTATE CANCER | 2021 |
|
RU2770983C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR PROSTATE CANCER | 2012 |
|
RU2521389C2 |
| PROGNOSTIC METHOD FOR INDIVIDUALS WITH PROSTATE CANCER | 2013 |
|
RU2669809C2 |
| METHODS OF TREATING ONCOLOGICAL DISEASES | 2011 |
|
RU2589513C2 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR BENIGN PROSTATE HYPERPLASIA AND PROSTATE CANCER | 2011 |
|
RU2464569C1 |
